Overview

  • Product nameAnti-GLB1 antibody
    See all GLB1 primary antibodies
  • Description
    Mouse monoclonal to GLB1
  • Tested applicationsSuitable for: WB, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment: KGQVWINGFN LGRYWPARGP QLTLFVPQHI LMTSAPNTIT VLELEWAPCS SDDPELCAVT FVDRPVIGSS VTYDHPSKPV EKRLMPPPPQ KNKDSWLDHV , corresponding to amino acids 578-678 of Human GLB1

Properties

Applications

Our Abpromise guarantee covers the use of ab55176 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
Flow Cyt
  • Application notesWB: Use at a concentration of 1-5 µg/ml.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionCleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans.
      Isoform 2 has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cancer cell types. In elastin producing cells, associates with tropoelastin intracellularly and functions as a recycling molecular chaperone which facilitates the secretions of tropoelastin and its assembly into elastic fibers.
    • Involvement in diseaseDefects in GLB1 are the cause of GM1-gangliosidosis type 1 (GM1G1) [MIM:230500]; also known as infantile GM1-gangliosidosis. GM1-gangliosidosis is an autosomal recessive lysosomal storage disease marked by the accumulation of GM1 gangliosides, glycoproteins and keratan sulfate primarily in neurons of the central nervous system. GM1G1 is characterized by onset within the first three months of life, central nervous system degeneration, coarse facial features, hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler syndrome, and rapidly progressive psychomotor deterioration. Urinary oligosaccharide levels are high. It leads to death usually between the first and second year of life.
      Defects in GLB1 are the cause of GM1-gangliosidosis type 2 (GM1G2) [MIM:230600]; also known as late infantile/juvenile GM1-gangliosidosis. GM1G2 is characterized by onset between ages 1 and 5. The main symptom is locomotor ataxia, ultimately leading to a state of decerebration with epileptic seizures. Patients do not display the skeletal changes associated with the infantile form, but they nonetheless excrete elevated amounts of beta-linked galactose-terminal oligosaccharides. Inheritance is autosomal recessive.
      Defects in GLB1 are the cause of GM1-gangliosidosis type 3 (GM1G3) [MIM:230650]; also known as adult or chronic GM1-gangliosidosis. GM1G3 is characterized by a variable phenotype. Patients show mild skeletal abnormalities, dysarthria, gait disturbance, dystonia and visual impairment. Visceromegaly is absent. Intellectual deficit can initially be mild or absent but progresses over time. Inheritance is autosomal recessive.
      Defects in GLB1 are the cause of mucopolysaccharidosis type 4B (MPS4B) [MIM:253010]; also known as Morquio syndrome B. MPS4B is a form of mucopolysaccharidosis type 4, an autosomal recessive lysosomal storage disease characterized by intracellular accumulation of keratan sulfate and chondroitin-6-sulfate. Key clinical features include short stature, skeletal dysplasia, dental anomalies, and corneal clouding. Intelligence is normal and there is no direct central nervous system involvement, although the skeletal changes may result in neurologic complications. There is variable severity, but patients with the severe phenotype usually do not survive past the second or third decade of life.
    • Sequence similaritiesBelongs to the glycosyl hydrolase 35 family.
    • Cellular localizationLysosome and Cytoplasm > perinuclear region. Localized to the perinuclear area of the cytoplasm but not to lysosomes.
    • Information by UniProt
    • Database links
    • Alternative names
      • Acid beta galactosidase antibody
      • Acid beta-galactosidase antibody
      • Beta galactosidase 1 antibody
      • Beta galactosidase antibody
      • Beta-galactosidase antibody
      • BGAL_HUMAN antibody
      • EBP antibody
      • EBP, included antibody
      • Elastin receptor 1 (67kD) antibody
      • Elastin receptor 1 67kDa antibody
      • Elastin receptor 1 antibody
      • Elastin receptor 1, included antibody
      • Elastin-binding protein, included antibody
      • ELNR1 antibody
      • Galactosidase beta 1 antibody
      • GLB 1 antibody
      • GLB1 antibody
      • Lactase antibody
      • MPS4B antibody
      • S-GAL, included antibody
      see all

    Anti-GLB1 antibody images



    • Predicted band size : 76 kDa
      GLB1 antibody (ab55176) at 1ug/lane + HeLa cell lysate at 25ug/lane.

    References for Anti-GLB1 antibody (ab55176)

    This product has been referenced in:
    • Wagner J  et al. Overexpression of the novel senescence marker ß-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. PLoS One 10:e0124366 (2015). WB, Flow Cyt, ICC/IF ; Human . Read more (PubMed: 25876105) »
    • Hasadsri L  et al. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284:6972-81 (2009). Read more (PubMed: 19129199) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab55176.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"